Brief: Orchard Therapeutics Receives EC Approval for Libmeldy To Treat Early-Onset Metachromatic Leukodystrophy
21/12/2020 12:08
Dec 21 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS RECEIVES EC APPROVAL FOR LIBMELDY™
FOR THE
TREATMENT OF EARLY-ONSET METACHROMATIC LEUKODYSTROPHY (MLD)
Source text for Eikon: ID:nGNX3MSM3F
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln